Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


22.10.2018

2 BMC Cancer
1 Br J Cancer
1 Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
1 Gynecol Oncol
1 Hum Pathol
1 Int J Gynaecol Obstet
2 Oncogene
1 Tumour Biol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. RAMSER M, Eichelberger S, Daster S, Weixler B, et al
    High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.
    BMC Cancer. 2018;18:425.
    PubMed     Text format     Abstract available

  2. SCHULER-TOPRAK S, Weber F, Skrzypczak M, Ortmann O, et al
    Estrogen receptor beta is associated with expression of cancer associated genes and survival in ovarian cancer.
    BMC Cancer. 2018;18:981.
    PubMed     Text format     Abstract available


    Br J Cancer

  3. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    PubMed     Text format     Abstract available


    Cancer Res


  4. Correction: RSF1 Is a Positive Regulator of NFkappaB-induced Gene Expression Required for Ovarian Cancer Chemoresistance.
    Cancer Res. 2018;78:6024.
    PubMed     Text format    


    Eur J Obstet Gynecol Reprod Biol

  5. HUANG J, Chen J, Huang Q
    Diagnostic value of HE4 in ovarian cancer: A meta-analysis.
    Eur J Obstet Gynecol Reprod Biol. 2018;231:35-42.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  6. KIM HS, Kim JY, Lee YJ, Kim SH, et al
    Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31153.
    PubMed     Text format     Abstract available


    Hum Pathol

  7. ARTS FA, Keogh L, Smyth P, O'Toole S, et al
    miR-223 potentially targets SWI/SNF complex protein SMARCD1 in Atypical Proliferative Serous Tumor and High Grade Ovarian Serous Carcinoma.
    Hum Pathol. 2017 Oct 24. pii: S0046-8177(17)30377.
    PubMed     Text format     Abstract available


    Int J Gynaecol Obstet

  8. MICHAAN N, Gortzak-Uzan L, Grisario D, Laskov I, et al
    Ethnicity-related trends in gynecologic malignancies in Israel, 1993-2013.
    Int J Gynaecol Obstet. 2018 May 9. doi: 10.1002/ijgo.12524.
    PubMed     Text format     Abstract available


    Oncogene

  9. NAGARAJ AB, Wang QQ, Joseph P, Zheng C, et al
    Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
    Oncogene. 2018;37:403-414.
    PubMed     Text format     Abstract available

  10. BIAN X, Gao J, Luo F, Rui C, et al
    PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Oncogene. 2017 Sep 25. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Tumour Biol

  11. OKLA K, Surowka J, Fraszczak K, Czerwonka A, et al
    Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Tumour Biol. 2018;40:1010428318804937.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: